Biomarker, Ovarian Cancer
Conditions
Brief summary
This clinical trial aims to investigate the role of biomarkers in guiding precision treatment for ovarian cancer. The study will explore the effectiveness of personalized treatment strategies based on specific biomarkers identified in ovarian cancer patients. By analyzing the correlation between biomarker profiles and treatment outcomes, the trial seeks to optimize treatment decisions and improve overall survival rates in ovarian cancer patients.
Interventions
GENETICSequencing of DNA, RNA, and Proteins
Sequencing of DNA, RNA, and Proteins for Tumor, Blood, Ascite, and other samples before and after treatment.
Sponsors
Tongji Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients diagnosed with ovarian cancer. * Willingness to undergo biomarker testing. * Ability to provide informed consent for participation in the study.
Exclusion criteria
* Inability to comply with study requirements or follow-up visits. * Previous participation in a conflicting clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Biomarker explorarion | 5 years | Blood, tumor, and other samples should be sequenced by RNA-seq, Next-Generation Sequencing, or proteomics to identify specific biomarkers associated with treatment response and prognosis in ovarian cancer. |
Countries
China
Outcome results
None listed